Thelansis

Cushing’s Syndrome (CS) Market Outlook Thelansis’s “Cushing’s Syndrome (CS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cushing’s Syndrome (CS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajec...

Cushing’s Syndrome (CS) Market Outlook Thelansis’s “Cushing’s Syndrome (CS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cushing’s Syndrome (CS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Cushing’s Syndrome (CS) Overview Cushing’s Disease (CD), the leading cause of endogenous Cushing’s Syndrome (CS), results from the persistent overproduction of ACTH by a pituitary corticotroph adenoma. CD predominantly affects females, with a female-to-male ratio of 4-5:1, except in prepubertal patients, where males are more commonly affected. The peak age of onset occurs between 25 and 40 years. CD symptoms include typical CS features...

 Cushing's Disease (CD), the leading cause of endogenous Cushing's Syndrome (CS), results from the persistent overproduction of ACTH by a pituitary corticotroph adenoma. CD predominantly affects females, with a female-to-male ratio of 4-5:1, except in prepubertal patients, where males are more commonly affected. The peak age of onset occurs between 25 and 40 years. CD symptoms include typical CS features like central obesity, facial rounding, hypercatabolism signs, skin hyperpigmentation, and, in some cases, corticotroph macro-adenoma, neurological complications. Cushing's syndrome can present with varying signs and symptoms. Prolonged exposure to elevated cortisol levels leads to evident manifestations such as weight gain, thin extremities, a rounded face, fat accumulation around the neck, a fatty hump between the shoulders, easy bruising, wide purple stretch marks, mainly on the abdomen, breasts, hips, and under the arms, and muscle weakness. The exact pathogenesis of pit...